AINDEX
Markets

GRI Bio, Inc. (GRI)

GRINASDAQ-CMBiotechnology: Pharmaceutical Preparations

$1.40

-0.0220 (-1.55%) today

At the close, Nov 16, 4:00 PM ET. Pre-market $1.41 +0.69%

-21.79% 1D
Market cap
$3.08m
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$1.36 to $64.12
Average volume
–
Previous close
$1.42

Analysts

1 covering

Buy1 buy, 0 hold, 0 sell

Targets a year out average $27.00, +1828.6% from here

$27.00now $1.40$27.00

Earnings

next estimate $-0.8300

Next report

Mar 2026

-76.9%

Jun 2026

+24.2%

Sep 2026

+17.9%

estimate reported, and the surprise

Financials

QuarterSep 2025Dec 2025Mar 2026Jun 2026
Revenue––––
Gross profit––––
Operating income-$3.36m-$2.66m-$2.00m-$1.65m
Net income-$3.36m-$2.66m-$2.00m-$1.64m

News

8 latest

The company

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ('NKT') cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ('iNKT') cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-CM
Region
North America
Website
gribio.com

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.